ATLANTA, May 20 /PRNewswire/ -- Germany will present itself as one of the world's leading regenerative medicine research locations at this year's BIO International Convention. Under the "Breakthroughs in Regenerative Medicines in Germany" banner, German experts will provide invaluable insight into the latest research results in the area of regenerative medicine in Germany. The German research landscape and the regulatory framework conditions will be introduced in a presentation in which the most recent industry successes will also be demonstrated.
Dr. Manfred Rudiger, CEO of Frankfurt-based t2cure GmbH, and Prof. Dr. Georg N. Duda, Vice Director of the Berlin-Brandenburg Center for Regenerative Therapies (BCRT), will also speak at the Germany Trade & Invest-organized event. Both are experts and active partners in the German research and enterprise landscape in the area of regenerative medicine.
Regenerative medicine offers rich and varied potential at a time when western social welfare states are confronted with the problem of rapidly aging populations and overloaded health systems. It is generally expected that not only should the quality of life of the patient be improved by regenerative treatments, but also that health systems be sustainably disburdened by eliminating protracted aftercare and complications.
Germany takes center-stage in the presentation as an innovative location with favorable research conditions. In this respect, highlighted in particular is the excellent cross-linking among German universities as well as with other research and development institutions. In combination with the strong political will to actively promote promising regenerative medicine projects, the high quality of existing research networks provide a strong argument for investment in Germany.
As well as highlighting German initiative-led successes in regenerative
medicine to date, the ev
|SOURCE Germany Trade and Invest|
Copyright©2009 PR Newswire.
All rights reserved